Compare TG Therapeutics Inc (TGTX) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Wix.Com Ltd — how do they compare? TG Therapeutics Inc trades at $49.6 (market cap $7.58B), while Wix.Com Ltd trades at $69.05 (market cap $2.88B). The key difference: TG Therapeutics Inc is far larger — about 2.6× Wix.Com Ltd's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| TGTX | WIX | |
|---|---|---|
Market Cap | $7.58B | $2.88B |
Sector | Health | Technology |
52-Week High | $59.06 | $184.24 |
52-Week Low | $26.94 | $40.43 |
Enterprise Value | $7.78B | $3.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
WIX stock trades at $68.78, up 10.18% today, with a bullish technical signal from moving averages. Revenue grew to $1.99B in 2025, but net income margin remains negative at -8.19%, and the company faces a securities class action. The P/E ratio is elevated at 62.84, indicating high growth expectations. Recent news highlights the launch of Symphony by Wix, an AI system for SMBs, amidst legal challenges.
The outlook is mixed: strong analyst consensus (65.85% buy rating) and a $79.75 price target suggest upside, but legal risks and negative cash flow in 2025 pose significant headwinds. Investors should weigh growth potential against execution and litigation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
